ABSTRACT PURPOSE: Current study is focused on extraction with methanol, purification, labeling with 131 I using iodogen method of the yarrow plant and investigating in vivo biological activity using biodistribution and imaging studies on healthy animal models. The aim of the study is to contribute plant extracts to discover new drugs in the diagnosis and treatment of several diseases. METHODS: Nine female and nine male healthy Wistar albino rats, which were approximately 100-150 g in weight, were used for biodistribution studies. For imaging studies four healthy male Balb-C mice were used. Quality control studies were done utilizing thin layer radio chromatography (TLRC) and high performance liquid chromatography (HPLC) methods. For biodistribution studies, 131 I radiolabeled Peak 7 ( 131 I-Peak 7) was sterilized and injected into the tail veil of rats and imaging studies were obtained using Kodak FX PRO in vivo Imaging System. RESULTS: The radiolabeling yield of each purified the bioactive extracts of the yarrow plant, seven peaks was between 79 and 92%. The highest radiolabeling yield was calculated for 131 I radiolabeled seventh peak ( 131 I-Peak 7) (92.78±5.04, n=5). For this reason the biodistribution and imaging studies were done for 131 I-Peak 7. That's why; these studies with Peak 7 were carried out. CONCLUSION: Peak 7 was radiolabeled with 131 I in high yield for using imaging and therapeutic studies in nuclear medical applications.
Introduction
The genus Achillea is represented by about 110-140 species mostly found in Europe and Asia and a few species native to northern Africa and North America 1 .About forty species of Achillea are located in Turkey 2 . Edirne is one of the places where members of Achillea family are located in yarrow particularly.
Yarrow (Achillea millefolium L. s. l.) which has been used as medicinal herb for a long time, is one of the most important drug used both in folk and official medicine today 3 . Achillea millefolium plants have been used for centuries for treat spasms, digestive complaints, menstruation disorders, urinary infections, anti inflammatory, spasmolytic, hemostatic, diarrhea, abdominal pain, stomach ache and other ailments 4 . Also it has been reported Achillea millefolium plants have some pharmacological effects such as antispasmodic, antimicrobial, analgesic, antipyretic, choleretic, cytotoxic, and estrogenic 5 . It is believed that these effects are mainly attributed to the flavonoid and phenolcarbonic acid complex 6 . Flavonoids are polyphenolic compounds that can be found in natural products, plants and fruits 7 .
Yarrow contains many bioactive compounds. Some of them are achilleine, apigenin, luteolin, azulene, camphor, coumarin, inulin, menthol, quercetin, rutin, succinic, salicylic and caffeic acids 3 . On the other hand, luteolin, quercetin, chrysin, and kaempferol have antiestrogenic effect 8 .
Iodine 131 is an important isotope of iodine which is used in diagnostic and therapeutic nuclear medicine due to its decay properties. Its half life is 8.04 days and decays through beta and gamma emissions 9 .
In this study; the bioactive components of the collected yarrow samples from Edirne were obtained by extraction, purification methods and MALDI/TOF spectra are used for the identification of them.
The aim of the present study was to radiolabel the bioactive extracts of the yarrow plants with 131 I using iodogen method and to investigate their in vivo biological activity using biodistribution and imaging studies in healthy animal models.
On the other hand, there is no study using the extracts of yarrow plant which have lots of pharmacologic activity, as radiolabeled compounds in the literature.
Methods
The experimental protocol was approved by the Institutional Animal Review Committee of Ege University, (Number: 2011-205) Izmir, Turkey. The rats and mice were kept according to the ethical principles of the Ege University.
Nine female and nine male healthy Wistar albino rats weighing 100 to 150g and four healthy male Balb-C mice weighing 20 to 25g were used. The animals were kept in light-darkcycles (12/12h) with free access to food and water.
Experimental Procedures
Plant material and extraction .
Purification of the extract with High Performance Liquid

Chromatography (HPLC)
The extract samples of the yarrow were purified by using HPLC. A low pressure gradient HPLC system (LC-10ATvp quaternary pump and SPD-10A/V UV detector with syringe injector equipped with a 20 µL loop and 5-µm RP-C18 column (250×4.6 mm I.D., Macharey-Nagel) was used for analytical and purification experiments. The chromatographic conditions were presented in Table 1 . 
Column
For analytical and purification experiments: RP-C18 (250x4.6 mm).
Flow rate
For analytical and purification experiments: 1.2 mL/min. 
Wave lenght 345 nm
Mobile phase
In vivo imaging studies
The imaging studies were performed using the Kodak FX 
Results
The chromatogram of the bioactive extract of the yarrow is shown in Figure 1 Retention time (R t ) value of Peak 7 was determined 37.88 minutes at the conditions shown in Table 1 . Basic fragments in yarrow and their theoretical LogP values according to ACD/I Lab (Version 6) was given in Table 3. According to Table 2 , it is thought that Peak 7 includes luteolin which have high lipophilicity. This result was also supported by MALDI-TOF structural analysis (Figures 2 and 3) . The % ID/g values of the Maximum bladder uptake for male rats is at 120 min. (11.59±6.14)
and for female rats is at 60 min. There is no significant alteration on the % ID/g of tissues from heart, lung, liver, small intestine, spleen, muscle, fat, thyroid, testis, head and blood. Experimental results obtained in current study demonstrated that the Peak 7 which is one of the bioactive components of Yarrow extract could be easily radiolabeled with 131 I radionuclide which means that should be radiolabeled with other iodine radioisotopes promising a wide use in Nuclear Medicine for both imaging and therapeutic agents.
Due to the recently described study, further insights into the cancer imaging potential of yarrow is supported and confirmed the traditional use and benefit of the yarrow plant. Current study is a contribution to the area of the plant extracts use for medicinal purposes.
Further investigations with animal models and cell culture experiments need to be performed to show that Peak 7 may be used as an imaging and/or a therapeutic agent because of the convenient properties 131 I radionuclide and its other radioisotopes.
Radiolabeled Peak 7, which is a component of yarrow plant extract, could be used as a novel plant origin agent for diagnosis and therapy of cancer.
Conclusion
Peak 7 was radiolabeled with 131 I in high yield for using imaging and therapeutic studies in nuclear medical applications.
